Erratum: (Hypertension (2014) 63:729 (739) DOI: 10.1161/HYPERTENSIONAHA.113.02526);Inhibition of mammalian target of rapamycin with rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN

Hypertension

Volumn 63, Issue 4, 2014, Pages 729-739

  Xu, Xihui ^a   Roe, Nathan D ^a   Weiser Evans, Mary C M ^b   Ren, Jun ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

autophagy; hypertrophic cardiomyopathy; PTEN; rapamycin

Indexed keywords

BECLIN 1; CRE RECOMBINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MYOSIN HEAVY CHAIN ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P62; RAPAMYCIN; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CONTROLLED STUDY; ENZYME INHIBITION; GENE DELETION; HEART MUSCLE CELL; HISTOLOGY; HOMEOSTASIS; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

AUTOPHAGY; HYPERTROPHIC CARDIOMYOPATHY; PTEN; RAPAMYCIN;

ANIMALS; AUTOPHAGY; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODELS, ANIMAL; HOMEOSTASIS; INTEGRASES; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VENTRICULAR MYOSINS;

EID: 84897046471     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYP.0000000000000040     Document Type: Erratum

References (42)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Heron M. Deaths: preliminary data for 2008. Natl Vital Stat Rep. 2012;59:1-51.
3. Maron BJ. Contemporary insights and strategies for risk stratifcation and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 2010;121:445-456.
4. Teekakirikul P, Padera RF, Seidman JG, Seidman CE. Hypertrophic car-diomyopathy: translating cellular cross talk into therapeutics. J Cell Biol. 2012;199:417-421.
5. Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, Bronson R, Franchini KG, Neel BG, Kontaridis MI. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121:1026-1043.
6. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocar-dial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737-749.
7. Oudit GY, Kassiri Z, Zhou J, Liu QC, Liu PP, Backx PH, Dawood F, Crackower MA, Scholey JW, Penninger JM. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res. 2008;78:505-514.
8. Oudit G Y, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449-471.
9. Kishimoto H, Hamada K, Saunders M, Backman S, Sasaki T, Nakano T, Mak TW, Suzuki A. Physiological functions of Pten in mouse tissues. Cell Struct Funct. 2003;28:11-21.
10. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-657.
11. McMahon J, Huang X, Yang J, Komatsu M, Yue Z, Qian J, Zhu X, Huang Y. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J Neurosci. 2012;32:15704-15714.
12. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN defciency is fully penetrant for prostate adeno-carcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol. 2009;174:1869-1879.
13. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol. 2007;47:443-467.
14. Wang RH, He JP, Su ML, et al. The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling. EMBO Mol Med. 2013;5:137-148.
15. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050-3055.
16. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107:1664-1670.
17. Boluyt MO, Zheng JS, Younes A, Long X, O'Neill L, Silverman H, Lakatta EG, Crow MT. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res. 1997;81:176-186.
18. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, Dart A, Du XJ. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fbrosis. J Hypertens. 2006;24:1663-1670.
19. Xu X, Hua Y, Nair S, Sreejayan N, Zhang Y, Ren J. Akt2 knockout preserves cardiac function in high-fat diet-induced obesity by rescuing cardiac autophagosome maturation. J Mol Cell Biol. 2013;5:61-63.
20. Xu X, Ren J. Unmasking the janus faces of autophagy in obesity-associated insulin resistance and cardiac dysfunction. Clin Exp Pharmacol Physiol. 2012;39:200-208.
21. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fghts disease through cellular self-digestion. Nature. 2008;451:1069-1075.
22. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27-42.
23. Nemchenko A, Chiong M, Turer A, Lavandero S, Hill JA. Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol. 2011;51:584-593.
24. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N. The role of autophagy during the early neonatal starvation period. Nature. 2004;432:1032-1036.
25. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, Nishida K, Hori M, Mizushima N, Otsu K. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 2007;13:619-624.
26. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, Richardson JA, Schneider MD, Yanagisawa M. Cardiomyocyte-specifc endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol. 2003;23:8226-8232.
27. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracel-lular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
28. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132-141.
29. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140:313-326.
30. Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005;171:603-614.
31. Xu X, Hueckstaedt LK, Ren J. Defciency of insulin-like growth factor 1 attenuates aging-induced changes in hepatic function: role of autophagy. J Hepatol. 2013;59:308-317.
32. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphory-lating Tsc2. Nat Cell Biol. 2002;4:658-665.
33. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 2000;14:2712-2724.
34. Sciarretta S, Zhai P, Shao D, Maejima Y, Robbins J, Volpe M, Condorelli G, Sadoshima J. Rheb is a critical regulator of autophagy during myocar-dial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation. 2012;125:1134-1146.
35. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, Levine B. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell. 2007;128:931-946.
36. Taneike M, Yamaguchi O, Nakai A, et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy. 2010;6:600-606.
37. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle. 2009;8:567-572.
38. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myo-cardial contractile dysfunction: role of autophagy. Basic Res Cardiol. 2011;106:1173-1191.
39. Choi JC, Worman HJ. Reactivation of autophagy ameliorates LMNA car-diomyopathy. Autophagy. 2013;9:110-111.
40. Pramanik MK, Iijima M, Iwadate Y, Yumura S. PTEN is a mechanosens-ing signal transducer for myosin II localization in Dictyostelium cells. Genes Cells. 2009;14:821-834.
41. Pal A, Barber TM, Van de Bunt M, Rudge SA, Zhang Q, Lachlan KL, Cooper NS, Linden H, Levy JC, Wakelam MJ, Walker L, Karpe F, Gloyn AL. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012;367:1002-1011.
42. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231-1241.